Zinc Absorption in Flakes Derived from Sprouted or Hydrothermally Processed Wheat
Launched by KU LEUVEN · Jan 24, 2024
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
The zinc study is a randomised crossover design with two different meals (control wheat flakes and flakes derived from sprouted wheat or flakes derived from hydrothermally processed wheat) spiked with a specific zinc isotope. The study contains two test groups (I and II) of 26 and 10 participants, respectively. Both test groups will consume the control wheat flakes, whereas test group I will consume the flakes from sprouted wheat and group II the flakes from hydrothermally processed wheat randomised over two test days. An intravenous dose of Zn will be given on day 1 of the study and the zi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI range 18.5-25.0 kg/m²
- • Regular diet with 3 meals a day (at least 5 times a week)
- Exclusion Criteria:
- • Intake of vitamin and/or mineral supplements during and 2 weeks before the stud
- • Intake of antibiotics 3 months prior to the study
- • Intake of medicines that have an impact on the gastrointestinal tract during and 2 weeks before the study
- • Previous or current gastrointestinal (e.g. Crohn's disease), endocrine or eating disorders or other gastrointestinal history
- • Previous or current substance/alcohol dependence or abuse (\> 2 units per day/14 units per week)
- • Currently smoking (have smoked in the last 28 days) or willingness to smoke during the study period
- • Pregnant or lactating or wishing to become pregnant in the period of the study
- • Allergy or intolerance to wheat (coeliac disease, gluten sensitivity) or citric acid
- • Adherence to vegan or vegetarian diets or special diets (weight loss, gluten-free etc...)
- • Blood donation in the 6 months prior to the study
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Patients applied
Trial Officials
Kristin Verbeke, Prof.
Principal Investigator
KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported